Industry news that matters to you.  Learn more

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular diagnostics®, today announces the expansion of its long-term collaboration agreement with Thermo Fisher Scientific to include development and commercialization of in vitro diagnostic (IVD) assays for the Applied Biosystems® 3500 Dx Series Genetic Analyzers. The company’s previously announced agreement focuses on the development of IVD oncology tests for the Ion PGM™ Dx System.

Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Development

Thermo Fisher Scientific today launched the Ion Torrent Developers Alliance Program to support the development and commercialization of molecular in vitro diagnostics and clinical research assays using targeted next-generation sequencing (NGS) technology.

Thermo Fisher Scientific Announces Expanded FDA Clearance for its B·R·A·H·M·S PCT Sepsis Biomarker

Thermo Fisher Scientific Inc., the world leader in serving science, recently announced it has received clearance from the U.S. Food and Drug Administration (FDA) that expands the clinical claims of the Thermo Scientific B·R·A·H·M·S PCT (procalcitonin) biomarker assay for sepsis risk assessment. PCT is a sensitive and specific biomarker of systemic bacterial infection. Clinicians can now use B·R·A·H·M·S PCT to help assess the response of septic patients to treatment by comparing a baseline PCT measurement with a PCT value taken on day four. The change in PCT over time, in conjunction with other laboratory findings and clinical assessments aids in assessing the cumulative 28-day risk of mortality for patients with severe sepsis or septic shock who are admitted to the intensive care unit.

Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific

Invivoscribe® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has signed a long-term strategic collaboration agreement with Thermo Fisher Scientific to develop multiple next-generation sequencing (NGS)-based, in vitro diagnostic (IVD) oncology tests on the Ion PGMTM Dx System.

Transcriptome Profiling Grants Launched to Support New Biomarker Discovery

Thermo Fisher Scientific will fast-track 12 translational research teams’ gene-expression profiling through an innovative grant program launched today. Selected applicants will receive free next-generation RNA sequencing services to further their research in the field of cancer genomics.